Delcath Systems, Inc.
DCTH
NASDAQ·Healthcare·Medical - Devices·Mkt cap $568.9M
$16.48
▲ 0.00%
P/E
—
Mkt Cap
$568.9M
52-Wk Range
$8.12–$17.42
52-Week Range
$8.12 - $17.42
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 42.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary hepatic delivery technology that reduces systemic chemotherapy exposure
- First-mover advantage in targeted liver cancer treatment with established European commercial presence
- Rare disease focus (uveal melanoma) with limited competitive alternatives and potential for expedited regulatory pathways
- Dual revenue model combining clinical development and commercial device sales
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Profitability at risk
FOCUS clinical trial results for metastatic uveal melanoma could unlock FDA approval and US market expansion
Value
Trading at 0.0x Medical Devices peers — a discount despite the growth profile.
Momentum
Hot
+50.6% over 3m
Quality
Excellent
Emerging growth company (36% revenue growth). Early stage with higher risk.
Dividend
None
No dividend
Smart-money signal
Who's buying DCTH right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 6, 2026
Reported EPS of $0.07 vs -$0.09 consensus (+178.5% surprise). Revenue of $29.1M vs $26.3M expected (+11.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+178.5%
Revenue trend · last 8Q
—
—
+530%
+211%
+84%
+37%
+26%
+21%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$11.2M
$15.1M
$19.8M
$24.2M
$20.6M
$20.7M
$25.0M
$29.1M
Margins · last 8Q
Gross
89.8%
Operating
8.2%
Profit
9.2%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 7, 2026
vs Industry
How DCTH stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related